Some of the things I look at in evaluating a company are is the product in demand. Will the public buy it? Is it safe? Are they well capitalized? What is my measured risk? What’s the upside?

So cydy checks all those boxes except for the risk, which is quite high and that’s why it’s priced so low. Their HIV drug is more than promising and it could be the standard of care if approved. Of course, there’s many other uses coming but for now , HIV.
Does anyone calculate whether that’s worth mote than a dollar?
Certainly everyone on this board is bullish on the stock but I sense almost everyone will ask “what was I thinking” remembering when it was .80 cents and the stock is $15 or much higher. I did this professionally for 41 years and this one has great potential.